We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Toxic Peptide from Wasp Venom Targets Cancer Cell Membrane Phospholipids

By LabMedica International staff writers
Posted on 15 Sep 2015
A toxic peptide component of the venom produced by a South American wasp effectively destroys some types of cancer cells through interactions with groups of phospholipids that are distributed abnormally on their cell membranes.

The Brazilian wasp Polybia paulista produces the bioactive host-defense peptide Polybia-MP1 (MP1) that has known anticancer properties. More...
Its ability to poke holes in cancer cell membranes has been attributed to excess phosphatidylserine (PS) and phosphatidylethanolamine (PE) on the outer membrane of cancer cells. Normal cells, which do not have PS or PE exposed on the cell surface, are not damaged by exposure to MP1.

Investigators at the University of Leeds (United Kingdom) and their collaborators at Sao Paulo State University (Brazil) studied the mode of action of MP1 by creating a series of model membranes with PE and PS distributed in a various patterns internally and externally. They used a combination of membrane permeability assays and imaging techniques in this endeavor.

Results published in the September 1, 2015, issue of Biophysical Journal revealed that PS lipids significantly enhanced the bound concentration of MP1 peptide on the membrane by a factor of seven to eight. Furthermore, a combination of membrane permeability assays and imaging techniques showed that PE significantly increased the susceptibility of the membrane to disruption by MP1 and caused an order-of-magnitude increase in membrane permeability by facilitating the formation of larger transmembrane pores.

Atomic-force microscopy imaging revealed differences in the pore formation mechanism with and without the presence of PE. With PE present, MP1 was more effective at disrupting the membrane, increasing the size of holes that it caused by a factor of 20 to 30. Therefore, PS and PE lipids synergistically combined to enhance the formation of membrane pores by MP1, implying that the combined enrichment of both these lipids in the outer membranes of cancer cells was highly significant for MP1’s anticancer action.

"Formed in only seconds, these large pores are big enough to allow critical molecules such as RNA and proteins to easily escape cells," said contributing author Dr. Joao Ruggiero Neto, professor of biophysics at Sao Paulo State University. "The dramatic enhancement of the permeabilization induced by the peptide in the presence of PE and the dimensions of the pores in these membranes was surprising."

"Understanding the mechanism of action of this peptide will help in translational studies to further assess the potential for this peptide to be used in medicine," said senior author Dr. Paul Beales, senior research fellow in structural molecular biology at the University of Leeds. "As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that."

Related Links:

University of Leeds
Sao Paulo State University 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.